ArticleEuropean journal of nuclear medicine and molecular imaging2026
[18F]fluorodeprenyl-D2 PET can detect and monitor astrogliosis in anti-LGI1-IgG autoimmune encephalitis.
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Diagnosing autoimmune encephalitis in psychiatry: clinical recommendations and unresolved challenges from the GENERATE network.Molecular psychiatry · 2026Review
- Review
- Feasibility of short imaging protocols for [European journal of nuclear medicine and molecular imaging · 2026Article
- Persistent Bilateral [Annals of clinical and translational neurology · 2026Article
- Hippocampal texture asymmetry features onFrontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo explore whether detecting local astrogliosis using [18F]fluorodeprenyl-D2 ([18F]F-DED) positron-emission-tomography (PET) uncovers and monitors inflammatory lesions in patients with anti-leucine-rich glioma-inactivated 1 antibody (LGI1-ab) associated autoimmune encephalitis (AE).
methodsDynamic [18F]F-DED PET scans (0–60 min post-injection) were obtained from a cohort of 15 LGI1-AE patients, 9 of whom were re-examined during the disease course, and from 15 controls. PET quantification was performed by kinetic modelling with an image derived input function and calculation of simplified standardized uptake values (SUV). [18F]F-DED SUVr (referenced to the straight gyrus) were analyzed for LGl1-AE target regions, compared between baseline and follow-up PET scans, used to investigate asymmetry of the mesial temporal lobe (MTL), and correlated to routine clinical data.
resultsSimplified [18F]F-DED PET quantification of the 30–60 min time-frame showed excellent agreement with kinetic modelling of the full dynamic imaging protocol. In LGI1-AE patients, [18F]F-DED SUVr values were significantly increased by 16% in the MTL (p = .002) and by 12% in the cerebellum (p = .014). [18F]F-DED signals in the MTL significantly declined during the course of the disease (mean follow-up time: 15 months, p = .006). MTL asymmetry (> 5%) of [18F]F-DED SUVr was present in 8/15 of LGI1-AE patients compared to 1/15 controls (p < .001) and showed marked decline between baseline and follow-up in LGI1-AE patients.
conclusionThis pilot study shows that [18F]F-DED PET is a promising tool to monitor regional astrogliosis in LGI1-AE patients and may provide a direct read-out of this important aspect of inflammatory disease activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.